Issue link: https://www.e-digitaleditions.com/i/1496325
32 April 2023 Inhalation Development and manufacturing of inhalation products Recipharm provides expertise in formulation devel- opment, device design and development, clinical trial supply, optimization and scale-up through full com- mercial supply for a range of inhalation technologies, covering both oral and nasal delivery. By providing our expertise in the development of combined drug/ device products together with commercial manufac- turing, we minimize hurdles and accelerate time to market. We have implemented technology platforms to provide drug formulation development expertise, comprehensive analytical support and manufacturing capabilities for a range of inhalation products. Recipharm UK: +44 1553 691000 www.recipharm.com Nasal formulation development and manufacturing Renaissance Lakewood offers contract development and manufacturing for nasal sprays. We can support all stages of projects, from formulation development through commercial manufacturing. With over 20 years of experience, our team can support a wide range of development activities including formulation development/optimization, spray method develop- ment, device selection, clinical trial material, process development and stability studies. In addition, we can support a wide range of nasal spray devices, includ- ing unit-dose, bi-dose and multidose (preserved and non-preserved formulations). Renaissance Lakewood US: +1 732 367-9000 www.renpharm.com Fully integrated solutions for dry powder inhalation Hovione is a fully integrated solution provider for dry powder inhalation (DPI). With extensive expe- rience in spray drying, jet milling and other particle engineering technologies, as well as precision capsule filling, Hovione is equipped to address challenges for small molecules and biologics. Hovione's science- based methodology, highly specialized devices, and state-of-the-art equipment for traditional and advanced platforms, enable the formulation of DPIs from low to high dosage with a streamlined approach from screening to commercial. Hovione Portugal: +351 21 982 9000 www.hovione.com DPI formulation development and manufacturing For 25 years, Lonza has provided integrated dry pow- der inhaler (DPI) development services to advance small molecules. Our premier particle engineering platform consists of integrated product development, including optimized particle engineering, precision micro-dosing, rapid screening, clinically relevant test- ing and GMP production. Our global facilities are equipped with world-class equipment and expertise to provide end-to-end services for respiratory drugs. Contact us for more information. Lonza Small Molecules US: +1 813 286-0404 www.lonza.com